Eddy Tsai, Chai ma , P eside t a d Chief Executive Office , comme ted:
“We believe AI is i c easi gly expa di g beyo d u de sta di g text, images, a d speech towa d i te p eti g eal-wo ld e vi o me tal i fo matio . This visio co ti ues to guide Ai os’ comme cializatio st ategy fo AI Nose. We believe futu e semico ducto ma ufactu i g, i dust ial i f ast uctu e, healthca e e vi o me ts, a d obotics applicatio s will i c easi gly equi e i tellige t e vi o me tal awa e ess, a d AI Nose co ti ues to adva ce steadily towa d that objective.”
“Du i g the fi st half of 2026, we co ti ued executi g ou comme cializatio oadmap by expa di g
“Si ce Decembe 2025, AI Nose has accumulated app oximately
“We a e e cou aged by the p og ess of ou comme cializatio activities. As existi g deployme ts co ti ue to adva ce, st ategic collabo atio s expa d, a d additio al eal-wo ld data st e gthe s the platfo m, we emai focused o executi g ou comme cializatio st ategy, expa di g eal-wo ld applicatio s, a d steadily adva ci g the lo g-te m developme t of ou Smell AI Platfo m.”
Ch istophe Lee, Chief Fi a cial Office of Ai os, added, “Ou seco d-qua te esults eflect Ai os’ co ti ued executio of its comme cializatio st ategy. We a e focused o suppo ti g AI Nose deployme ts ac oss semico ducto ma ufactu i g, i dust ial i f ast uctu e, healthca e, a d othe eal-wo ld e vi o me ts while adva ci g comme cializatio i itiatives a d expa di g st ategic collabo atio s that st e gthe the Compa y’s lo g-te m fou datio . We co ti ue to believe ou activities will help suppo t b oade eve ue ge e atio oppo tu ities i the seco d half of 2026.”
M . Lee co ti ued, “We emai committed to discipli ed capital allocatio a d fi a cial ma ageme t while suppo ti g ou co e comme cializatio st ategy, tech ology developme t, a d deployme t p io ities. We will co ti ue focusi g o ope atio al efficie cy, st ategic deployme t activities, a d fi a cial discipli e as we execute ou lo g-te m comme cializatio st ategy.”
Adva ced deployme ts associated with the p eviously a ou ced i itial $2.1 millio comme cial a a geme t i backe d semico ducto ma ufactu i g e vi o me ts.
Co ti ued pilot p og ams i selected f o t-e d semico ducto e vi o me ts.
Expa ded AI Nose deployme t a d validatio activities ac oss i dust ial a d healthca e i f ast uctu e e vi o me ts, i cludi g facility mo ito i g, safety, ve tilatio , equipme t, a d chemical ha dli g applicatio s.
Expa ded esea ch activities i volvi g eme ge cy ca e e vi o me ts a d exhaled b eath patte a alysis.
Co ti ued obotics- elated pilot a d deployme t activities.
Suppo ted use-case expa sio th ough cha el a d i teg atio pa t e ships.
Co ti ued developme t of Smell ID datasets a d smell la guage model capabilities usi g deployme t a d pilot data.
Ai os is focused o executio , deployme t, Smell ID dataset expa sio , smell la guage model developme t, a d st ategic comme cial expa sio , suppo ti g its lo g-te m objective of adva ci g AI Nose as a scalable Smell AI platfo m fo eal-wo ld i f ast uctu e e vi o me ts.
AI Nose digitizes sce t i to Smell ID, a AI-d ive fo m of sce t i tellige ce. The full-stack elect o ic ose platfo m i teg ates high-p ecisio MEMS se so a ays with p op ieta y AI algo ithms desig ed to suppo t ppb-level sce t detectio se sitivity, subject to applicatio co ditio s a d deployme t co figu atio s. Smell ID co ve ts a alog sce t sig als i to st uctu ed, actio able data, while the p op ieta y Smell La guage Model (SLM) is desig ed to lea , classify, a d co textualize complex sce t patte s ove time.
Built upo mo e tha a decade of accumulated sce t data a d deep medtech expe tise, AI Nose is desig ed to suppo t co ti uous mo ito i g, p edictive a alysis, a d eal-time ale ts ac oss i dust ial a d ma ufactu i g e vi o me ts. AI Nose is offe ed u de a SmellTech-as-a-Se vice a chitectu e, i te ded to suppo t o goi g access to sce t i tellige ce, a alytics, a d AI-d ive i sights th ough subsc iptio -based deployme t models.
Ai os, I c. (NASDAQ:AIMD) is a dual-platfo m AI a d biotech compa y pio ee i g smelltech a d immu e the apeutics. Its AI Nose platfo m a d smell la guage model (SLM) digitize sce t i to Smell ID, a machi e- eadable data fo mat, powe i g i tellige t se si g ac oss obotics, sma t facto ies, a d healthca e. The compa y also develops VELDONA®, a low-dose o al i te fe o ta geti g a e, autoimmu e, a d i fectious diseases. Ai os, a fusio of “AI” a d “Nose,” is edefi i g machi e pe ceptio fo the se so y age. To lea mo e, visit https://www.ai os.com. Follow Ai os o X, fo me ly k ow as Twitte , (@Ai osI c) a d Li kedI to stay up-to-date. Visit media oom https://ai os.suite.access ewswi e.com.
Ce tai stateme ts i this p ess elease a e fo wa d-looki g stateme ts withi the mea i g of Sectio 27A of the Secu ities Act of 1933, as ame ded, a d Sectio 21E of the Secu ities Excha ge Act of 1934, as ame ded. All stateme ts othe tha stateme ts of histo ical fact a e fo wa d-looki g stateme ts. Fo wa d-looki g stateme ts a e based o ma ageme t’s cu e t assumptio s a d expectatio s of futu e eve ts a d t e ds, which affect o may affect the Compa y’s busi ess, st ategy, ope atio s o fi a cial pe fo ma ce, a d actual esults a d othe eve ts may diffe mate ially f om those exp essed o implied i such stateme ts due to ume ous isks a d u ce tai ties. Fo wa d-looki g stateme ts a e i he e tly subject to isks a d u ce tai ties, some of which ca ot be p edicted o qua tified. The e a e a umbe of impo ta t facto s that could cause actual esults, developme ts, busi ess decisio s o othe eve ts to diffe mate ially f om those co templated by the fo wa d-looki g stateme ts i this p ess elease. These facto s i clude, amo g othe thi gs, ou expectatio that we will i cu et losses fo the fo eseeable futu e; ou ability to become p ofitable; ou ability to aise additio al capital to co ti ue ou p oduct developme t; ou ability to accu ately p edict ou futu e ope ati g esults; ou ability to adva ce ou cu e t o futu e p oduct ca didates th ough cli ical t ials, obtai ma keti g app oval a d ultimately comme cialize a y p oduct ca didates we develop; the ability to obtai a d mai tai egulato y app oval of ou p oduct ca didates; delays i completi g the developme t a d comme cializatio of ou cu e t a d futu e p oduct ca didates; developi g a d comme cializi g additio al p oducts, i cludi g diag ostic testi g devices; ou ability to compete i the ma ketplace; complia ce with applicable laws, egulatio s a d ta iffs, a d facto s desc ibed i the Risk Facto s sectio of ou public fili gs with the Secu ities a d Excha ge Commissio (SEC). Because fo wa d-looki g stateme ts a e i he e tly subject to isks a d u ce tai ties, you should ot ely o these fo wa d-looki g stateme ts as p edictio s of futu e eve ts. These fo wa d-looki g stateme ts speak o ly as of the date of this p ess elease a d, except to the exte t equi ed by applicable law, the Compa y u de takes o obligatio to update o evise these stateme ts, whethe as a esult of a y ew i fo matio , futu e eve ts a d developme ts o othe wise.
Co tact I fo matio I vesto Relatio s
Ju e 30, | Decembe 31, | 2026 | 2025 |
Th ee mo ths e ded Ju e 30, | Six mo ths e ded Ju e 30, | 2026 | 2025 | 2026 | 2025 |
